The in vitro activities of TP-271, a novel fluorocycline antimicrobial were studied against 22 isolates of Mycobacterium abscessus, 22 isolates of Mycobacterium fortuitum and 19 isolates of Nocardia spp by a microtiter broth dilution method. The MIC 90 for M. abscessus, M. fortuitum, and Nocardia spp, was 0.5µg/ml, 0.03µg/ml, and 8µg/ml respectively. TP-271 was significantly more active than the respective control drug in virtually all tests. (2). The most common clinical form of Nocardia infection is pulmonary nocardiosis, with and without 7 dissemination followed by skin and soft tissue infection (5). 8
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M. abscessus and M. fortuitum are rapidly growing mycobacteria that are primarily associated with 1 opportunistic infections in immunocompromised subjects (2).Patients with bronchiectasis are at increased 2 risk of M. abscessus infection, especially in those with cystic fibrosis. Other manifestations of M. 3 abscessus infection include localized skin infections, post-operative wound infections and infection of 4 implanted medical devices. M. fortuitum is a relatively rare pathogen, even in immunocompromised 5 individuals, but has been associated with skin infections and hospital acquired post-operative infections 6 (2). The most common clinical form of Nocardia infection is pulmonary nocardiosis, with and without 7 dissemination followed by skin and soft tissue infection (5). 8
While Nocardia remains susceptible to trimethoprim-sulfamethoxazole in the majority of cases, effective 13 alternative oral therapy is lacking. Mortality from pulmonary nocardiosis remains high, in the range of 14
15-40% (5, 8). 15
TP-271 is a novel fully-synthetic fluorocycline antimicrobial, related to tetracycline ( Fig.1; 1, 11 ). It has 16 been shown to have potent broad-spectrum in vitro and in vivo activity against multiple community 17 sealing film (Exel Scientific, Wrightwood, CA) prior to being incubated at 37 0 C in ambient air prior to 51 reading (4 days for M. abscessus and 2-3 days for M. fortuitum ). Each isolate was tested in duplicate. 52
The CLSI recommends a 4-day incubation period for Nocardia; however, some of our isolates grew 53 slowly, requiring 7 days of incubation. For consistency all Nocardia plates were incubated for 7 days. 54
The MIC was defined as the lowest concentration of antimicrobial agent yielding no visible turbidity. 55
The MIC 50 and MIC 90 of TP-271 and MOX against M. abscessus isolates were 0.25µg/ml, 0.5µg/ml andThe MIC 50 and MIC 90 for TP-271, DOX, and AMK against M. fortuitum isolates were 0.015µg/ml and 61 0.06µg/ml, 32µg/ml and 128µg/ml, and 0.25µg/ml and 2µg/ml respectively ( Table 2 ). The MIC range for 62 TP-271 was ≤0.001 -0.125µg/ml, the range for DOX was ≤0.25-256µg/ml, and the range for AMK was 63 0.06 -2µg/ml. 64
The MIC 50 and MIC 90 for TP-271 and TET against Nocardia spp. were 2µg/ml and 8µg/ml and 32µg/ml 65 and 64µg/ml respectively ( Table 3 ). The MIC range for TP-271 was 0.06 -16µg/ml and the range for 66 DOX was 2 -64µg/ml. 67
Our results indicate that TP-271 has promising in vitro activity against M. abscessus, and M. fortuitum 68 isolates with somewhat less activity against Nocardia spp. The activity of TP271 was much better than 69 that of other orally available tetracycline related compounds (9). Infections due to these organisms are not 70 common. Treatment of these infections is challenging, particularly for M. abscessus due to the lack of 71 effective agents and the immunosuppressed population affected. It appears that further evaluation of TP-72 271 in animal studies should be performed to assess its potential in vivo activity. 
